U.S. patent application number 11/736909 was filed with the patent office on 2007-08-09 for bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
This patent application is currently assigned to Boehringer Ingelheim International GmbH. Invention is credited to Frank HIMMELSBACH, Flavio Solca.
Application Number | 20070185081 11/736909 |
Document ID | / |
Family ID | 34577291 |
Filed Date | 2007-08-09 |
United States Patent
Application |
20070185081 |
Kind Code |
A1 |
HIMMELSBACH; Frank ; et
al. |
August 9, 2007 |
Bicyclic heterocylces, pharmaceutical compositions containing these
compounds, their use and processes for preparing them
Abstract
The present invention relates to bicyclic heterocycles of
general formula ##STR1## wherein R.sup.a, R.sup.b, R.sup.c,
R.sup.d, R.sup.e and X are defined as in claim 1, the tautomers,
the stereoisomers, the mixtures thereof and the salts thereof,
particularly the physiologically acceptable salts thereof with
inorganic or organic acids, which have valuable pharmacological
properties, particularly an inhibitory effect on signal
transduction mediated by tyrosine kinases, the use thereof for
treating diseases, particularly tumoral diseases and benign
prostatic hyperplasia (BPH), diseases of the lungs and respiratory
tract, and the preparation thereof.
Inventors: |
HIMMELSBACH; Frank;
(Mittelbiberach, DE) ; Solca; Flavio; (Wien,
AT) |
Correspondence
Address: |
MICHAEL P. MORRIS;BOEHRINGER INGELHEIM CORPORATION
900 RIDGEBURY ROAD
P. O. BOX 368
RIDGEFIELD
CT
06877-0368
US
|
Assignee: |
Boehringer Ingelheim International
GmbH
Ingelheim
DE
|
Family ID: |
34577291 |
Appl. No.: |
11/736909 |
Filed: |
April 18, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10778985 |
Feb 13, 2004 |
7223749 |
|
|
11736909 |
Apr 18, 2007 |
|
|
|
60452280 |
Mar 5, 2003 |
|
|
|
Current U.S.
Class: |
514/211.15 ;
540/544 |
Current CPC
Class: |
C07D 413/12 20130101;
C07D 413/14 20130101 |
Class at
Publication: |
514/211.15 ;
540/544 |
International
Class: |
A61K 31/554 20060101
A61K031/554; C07D 267/02 20060101 C07D267/02 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 20, 2003 |
DE |
103 07 165 |
Claims
1. A bicyclic heterocycle of formula ##STR29## wherein R.sup.a
denotes a hydrogen atom or a C.sub.1-4-alkyl group, R.sup.b denotes
a phenyl, benzyl or 1-phenylethyl group, wherein the phenyl nucleus
in each case is substituted by the groups R.sup.1 to R.sup.3, while
R.sup.1 and R.sup.2, which may be identical or different, in each
case denote a hydrogen, fluorine, chlorine, bromine or iodine atom,
a C.sub.1-4-alkyl, hydroxy, C.sub.1-4-alkoxy, C.sub.2-3-alkenyl or
C.sub.2-3-alkynyl group, an aryl, aryloxy, arylmethyl or
arylmethoxy group, a heteroaryl, heteroaryloxy, heteroarylmethyl or
heteroarylmethoxy group, a methyl or methoxy group substituted by 1
to 3 fluorine atoms or cyano, nitro or amino group, and R.sup.3
denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl or
trifluoromethyl group, R.sup.c denotes a hydrogen atom or a
fluorine, chlorine or bromine atom, a hydroxy or C.sub.1-4-alkyloxy
group, a methoxy group substituted by 1 to 3 fluorine atoms, an
ethyloxy group substituted by 1 to 5 fluorine atoms, a
C.sub.2-4-alkyloxy group which is substituted by a group R.sup.4,
while R.sup.4 denotes a hydroxy, C.sub.1-3-alkyloxy,
C.sub.3-6-cycloalkyloxy, C.sub.3-6-cycloalkyl-C.sub.1-3-alkyloxy,
amino, C.sub.1-3-alkylamino, di-(C.sub.1-3-alkyl)amino,
bis-(2-C.sub.1-3-alkyloxy-ethyl)-amino,
bis-(3-C.sub.1-3-alkyloxy-propyl)-amino, pyrrolidin-1-yl,
piperidin-1-yl, homopiperidin-1-yl, morpholin-4-yl,
homomorpholin-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)-piperazin-1-yl, homopiperazin-1-yl or
4-(C.sub.1-3-alkyl)-homopiperazin-1-yl group, a
C.sub.3-7-cycloalkyloxy or C.sub.3-7-cycloalkyl-C.sub.1-4-alkyloxy
group, a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy or
tetrahydropyran-4-yloxy group, a
tetrahydrofuranyl-C.sub.1-4-alkyloxy or
tetrahydropyranyl-C.sub.1-4-alkyloxy group, a pyrrolidin-3-yloxy,
piperidin-3-yloxy or piperidin-4-yloxy group, a
1-(C.sub.1-3-alkyl)-pyrrolidin-3-yloxy,
1-(C.sub.1-3-alkyl)-piperidin-3-yloxy or
1-(C.sub.1-3-alkyl)piperidin-4-yloxy group, a C.sub.1-4-alkoxy
group which is substituted by a pyrrolidinyl, piperidinyl or
homopiperidinyl group substituted in the 1 position by the group
R.sup.5, where R.sup.5 denotes a hydrogen atom or a C.sub.1-3-alkyl
group, or a C.sub.1-4-alkoxy group which is substituted by a
morpholinyl or homomorpholinyl group substituted in the 4 position
by the group R.sup.5, where R.sup.5 is as hereinbefore defined,
R.sup.e and R.sup.d, which may be identical or different, in each
case denote a hydrogen atom or a C.sub.1-3-alkyl group and X
denotes a methyne group substituted by a cyano group or a nitrogen
atom, while by the aryl groups mentioned in the definition of the
above groups is meant in each case a phenyl group which is mono- or
disubstituted by R.sup.6, while the substituents may be identical
or different and R.sup.6 denotes a hydrogen atom, a fluorine,
chlorine, bromine or iodine atom or a C.sub.1-3-alkyl, hydroxy,
C.sub.1-3-alkyloxy, difluoromethyl, trifluoromethyl,
difluoromethoxy, trifluoromethoxy or cyano group, by the heteroaryl
groups mentioned in the definition of the above groups is meant a
pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl group, while the
above-mentioned heteroaryl groups are mono- or disubstituted in
each case by the group R.sup.6, while the substituents may be
identical or different and R.sup.6 is as hereinbefore defined, and
unless otherwise stated, the above-mentioned alkyl groups may be
straight-chain or branched, a tautomer or a stereoisomer thereof,
or a mixture of such thereof, or a salt thereof.
2. The bicyclic heterocycle of formula I according to claim 1,
wherein R.sup.a denotes a hydrogen atom, R.sup.b denotes a phenyl
group substituted by the groups R.sup.1 to R.sup.3, while R.sup.1
denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl,
trifluoromethyl or ethynyl group, a phenyloxy or phenylmethoxy
group, while the phenyl moiety of the above-mentioned groups is
optionally substituted by a fluorine or chlorine atom, or a
pyridinyloxy or pyridinylmethoxy group, while the pyridinyl moiety
of the above-mentioned groups is optionally substituted by a methyl
or trifluoromethyl group, R.sup.2 denotes a hydrogen, fluorine or
chlorine atom and R.sup.3 denotes a hydrogen atom, R.sup.c denotes
a hydrogen atom, a C.sub.1-3-alkyloxy group, a
C.sub.4-6-cycloalkyloxy or C.sub.3-6-cycloalkyl-C.sub.1-2-alkyloxy
group, a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,
tetrahydropyran-4-yloxy, tetrahydrofuranyl-C.sub.1-2-alkyloxy or
tetrahydropyranyl-C.sub.1-2-alkyloxy group, an ethyloxy group which
is substituted in the 2 position by a group R.sup.4, where R.sup.4
denotes a hydroxy, C.sub.1-3-alkyloxy, amino, C.sub.1-3-alkylamino,
di-(C.sub.1-3-alkyl)amino, bis-(2-methoxyethyl)-amino,
pyrrolidin-1-yl, piperidin-1-yl, homopiperidin-1-yl,
morpholin-4-yl, homomorpholin-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)-piperazin-1-yl, homopiperazin-1-yl or
4-(C.sub.1-3-alkyl)-homopiperazin-1-yl group, a propyloxy group
which is substituted by a group R.sup.4 in the 3 position, while
R.sup.4 is as hereinbefore defined, or a butyloxy group which is
substituted by a group R.sup.4 in the 4 position, while R.sup.4 is
as hereinbefore defined, R.sup.e and R.sup.d, which may be
identical or different, in each case denote a hydrogen atom or a
methyl group and X denotes a nitrogen atom, while, unless otherwise
stated, the above-mentioned alkyl groups may be straight-chain or
branched, a tautomer or a stereoisomer thereof, or a mixture of
such thereof, or a salt thereof.
3. The bicyclic heterocycle of formula I according to claim 1,
wherein R.sup.a denotes a hydrogen atom, R.sup.b denotes a
3-ethynylphenyl, 3-bromophenyl, 3,4-difluorophenyl or
3-chloro-4-fluoro-phenyl group, R.sup.c denotes a hydrogen atom, a
methoxy, ethyloxy, 2-(methoxy)ethyloxy,
3-(morpholin-4-yl)propyloxy, cyclobutyloxy, cyclopentyloxy,
cyclohexyloxy, cyclopropylmethoxy, cyclopentylmethoxy,
tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,
tetrahydropyran-4-yloxy, tetrahydrofuran-2-yl methoxy,
tetrahydrofuran-3-yl methoxy or tetrahydropyran-4-ylmethoxy group,
R.sup.e and R.sup.d in each case denote a hydrogen atom and X
denotes a nitrogen atom, a tautomer or a stereoisomer thereof, a
mixture of such thereof, or a salt thereof.
4. The bicyclic heterocycle of formula I according to claim 1,
wherein R.sup.a denotes a hydrogen atom, R.sup.b denotes a
3-chloro-4-fluoro-phenyl group, R.sup.c denotes a
tetrahydrofuran-3-yloxy group, R.sup.e and R.sup.d in each case
denote a hydrogen atom and X denotes a nitrogen atom, a tautomer or
a stereoisomer thereof, or a mixture of such thereof or a salt
thereof.
5. The following compound of formula I according to claim 1:
4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-bu-
ten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline or a
salt thereof.
6. The physiologically acceptable salt of a compound according to
claim 1 with an inorganic or organic acid, or a mixture thereof, or
a base.
7. A pharmaceutical composition comprising a compound according to
claim 1 or a physiologically acceptable salt thereof and one or
more inert carriers and/or diluents.
8. A method for treating in a warm-blooded animal which comprises
administering to said animal a therapeutically effective amount of
a compound according to claim 1.
9. A method for preventing or treating diseases of the airways and
lungs in a warm-blooded animal which comprises administering to
said animal a therapeutically effective amount of a compound
according to claim 1.
10. A method for treating diseases of the gastrointestinal tract or
bile duct or gall bladder in a warm-blooded animal which comprises
administering to said animal a therapeutically effective amount of
a compound according to claim 1.
Description
[0001] The present invention relates to bicyclic heterocycles of
general formula ##STR2## the tautomers, the stereoisomers, the
mixtures thereof and the salts thereof, particularly the
physiologically acceptable salts thereof with inorganic or organic
acids, which have valuable pharmacological properties, particularly
an inhibitory effect on signal transduction mediated by tyrosine
kinases, the use thereof for treating diseases, particularly
tumoral diseases and benign prostatic hyperplasia (BPH), diseases
of the lungs and respiratory tract, and the preparation
thereof.
[0002] In the above general formula I
[0003] R.sup.a denotes a hydrogen atom or a C.sub.1-4-alkyl
group,
[0004] R.sup.b denotes a phenyl, benzyl or 1-phenylethyl group,
wherein the phenyl nucleus in each case is substituted by the
groups R.sup.1 to R.sup.3, while [0005] R.sup.1 and R.sup.2, which
may be identical or different, in each case denote a hydrogen,
fluorine, chlorine, bromine or iodine atom, [0006] a
C.sub.1-4-alkyl, hydroxy, C.sub.1-4-alkoxy, C.sub.2-3-alkenyl or
C.sub.2-3-alkynyl group, [0007] an aryl, aryloxy, arylmethyl or
arylmethoxy group, [0008] a heteroaryl, heteroaryloxy,
heteroarylmethyl or heteroarylmethoxy group, [0009] a methyl or
methoxy group substituted by 1 to 3 fluorine atoms or [0010] a
cyano, nitro or amino group, and [0011] R.sup.3 denotes a hydrogen,
fluorine, chlorine or bromine atom, [0012] a methyl or
trifluoromethyl group,
[0013] R.sup.c denotes a hydrogen atom or a fluorine, chlorine or
bromine atom,
[0014] a hydroxy or C.sub.1-4-alkyloxy group,
[0015] a methoxy group substituted by 1 to 3 fluorine atoms,
[0016] an ethyloxy group substituted by 1 to 5 fluorine atoms,
[0017] a C.sub.2-4-alkyloxy group which is substituted by a group
R.sup.4, while [0018] R.sup.4 denotes a hydroxy,
C.sub.1-3-alkyloxy, C.sub.3-6-cycloalkyloxy,
C.sub.3-6-cycloalkyl-C.sub.1-3-alkyloxy, amino,
C.sub.1-3-alkylamino, di-(C.sub.1-3-alkyl)amino,
bis-(2-C.sub.1-3-alkyloxy-ethyl)-amino,
bis-(3-C.sub.1-3-alkyloxy-propyl)-amino, pyrrolidin-1-yl,
piperidin-1-yl, homopiperidin-1-yl, morpholin-4-yl,
homomorpholin-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)-piperazin-1-yl, homopiperazin-1-yl or
4-(C.sub.1-3-alkyl)-homopiperazin-1-yl group,
[0019] a C.sub.3-7-cycloalkyloxy or
C.sub.3-7-cycloalkyl-C.sub.1-4-alkyloxy group,
[0020] a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy or
tetrahydropyran-4-yloxy group,
[0021] a tetrahydrofuranyl-C.sub.1-4-alkyloxy or
tetrahydropyranyl-C.sub.1-4-alkyloxy group,
[0022] a pyrrolidin-3-yloxy, piperidin-3-yloxy or piperidin-4-yloxy
group,
[0023] a 1-(C.sub.1-3-alkyl)-pyrrolidin-3-yloxy,
1-(C.sub.1-3-alkyl)-piperidin-3-yloxy or
1-(C.sub.1-3-alkyl)-piperidin-4-yloxy group,
[0024] a C.sub.1-4-alkoxy group which is substituted by a
pyrrolidinyl, piperidinyl or homopiperidinyl group substituted in
the 1 position by the group R.sup.5, where [0025] R.sup.5 denotes a
hydrogen atom or a C.sub.1-3-alkyl group,
[0026] or a C.sub.1-4-alkoxy group which is substituted by a
morpholinyl or homomorpholinyl group substituted in the 4 position
by the group R.sup.5, where R.sup.5 is as hereinbefore defined,
[0027] R.sup.e and R.sup.d, which may be identical or different, in
each case denote a hydrogen atom or a C.sub.1-3-alkyl group and
[0028] X denotes a methyne group substituted by a cyano group or a
nitrogen atom,
[0029] while by the aryl groups mentioned in the definition of the
above groups is meant in each case a phenyl group which is mono- or
disubstituted by R.sup.6, while the substituents may be identical
or different and [0030] R.sup.6 denotes a hydrogen atom, a
fluorine, chlorine, bromine or iodine atom or a C.sub.1-3-alkyl,
hydroxy, C.sub.1-3-alkyloxy, difluoromethyl, trifluoromethyl,
difluoromethoxy, trifluoromethoxy or cyano group,
[0031] by the heteroaryl groups mentioned in the definition of the
above groups is meant a pyridinyl, pyridazinyl, pyrimidinyl or
pyrazinyl group, while the above-mentioned heteroaryl groups are
mono- or disubstituted in each case by the group R.sup.6, while the
substituents may be identical or different and R.sup.6 is as
hereinbefore defined, and
[0032] unless otherwise stated, the above-mentioned alkyl groups
may be straight-chain or branched.
[0033] Preferred compounds of the above general formula I are those
wherein
[0034] R.sup.a denotes a hydrogen atom,
[0035] R.sup.b denotes a phenyl group substituted by the groups
R.sup.1 to R.sup.3, while [0036] R.sup.1 denotes a hydrogen,
fluorine, chlorine or bromine atom, [0037] a methyl,
trifluoromethyl or ethynyl group, [0038] a phenyloxy or
phenylmethoxy group, while the phenyl moiety of the above-mentioned
groups is optionally substituted by a fluorine or chlorine atom, or
[0039] a pyridinyloxy or pyridinylmethoxy group, while the
pyridinyl moiety of the above-mentioned groups is optionally
substituted by a methyl or trifluoromethyl group, [0040] R.sup.2
denotes a hydrogen, fluorine or chlorine atom and [0041] R.sup.3
denotes a hydrogen atom,
[0042] R.sup.c denotes a hydrogen atom,
[0043] a C.sub.1-3-alkyloxy group,
[0044] a C.sub.4-6-cycloalkyloxy or
C.sub.3-6-cycloalkyl-C.sub.1-2-alkyloxy group,
[0045] a tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,
tetrahydropyran-4-yloxy, tetrahydrofuranyl-C.sub.1-2-alkyloxy or
tetrahydropyranyl-C.sub.1-2-alkyloxy group,
[0046] an ethyloxy group which is substituted in the 2 position by
a group R.sup.4, where [0047] R.sup.4 denotes a hydroxy,
C.sub.1-3-alkyloxy, amino, C.sub.1-3-alkylamino,
di-(C.sub.1-3-alkyl)amino, bis-(2-methoxyethyl)-amino,
pyrrolidin-1-yl, piperidin-1-yl, homopiperidin-1-yl,
morpholin-4-yl, homomorpholin-4-yl, piperazin-1-yl,
4-(C.sub.1-3-alkyl)-piperazin-1-yl, homopiperazin-1-yl or
4-(C.sub.1-3-alkyl)-homopiperazin-1-yl group,
[0048] a propyloxy group which is substituted by a group R.sup.4 in
the 3 position, while R.sup.4 is as hereinbefore defined, or
[0049] a butyloxy group which is substituted by a group R.sup.4 in
the 4 position, while R.sup.4 is as hereinbefore defined,
[0050] R.sup.e and R.sup.d, which may be identical or different, in
each case denote a hydrogen atom or a methyl group and
[0051] X denotes a nitrogen atom,
[0052] while, unless otherwise stated, the above-mentioned alkyl
groups may be straight-chain or branched,
[0053] the tautomers, their stereoisomers, the mixtures thereof and
the salts thereof.
[0054] Particularly preferred compounds of the above general
formula I are those wherein
[0055] R.sup.a denotes a hydrogen atom,
[0056] R.sup.b denotes a 3-ethynylphenyl, 3-bromophenyl,
3,4-difluorophenyl or 3-chloro-4-fluoro-phenyl group,
[0057] R.sup.c denotes a hydrogen atom,
[0058] a methoxy, ethyloxy, 2-(methoxy)ethyloxy,
3-(morpholin-4-yl)propyloxy, cyclobutyloxy, cyclopentyloxy,
cyclohexyloxy, cyclopropylmethoxy, cyclopentylmethoxy,
tetrahydrofuran-3-yloxy, tetrahydropyran-3-yloxy,
tetrahydropyran-4-yloxy, tetrahydrofuran-2-yl methoxy,
tetrahydrofuran-3-yl methoxy or tetrahydropyran-4-ylmethoxy
group,
[0059] R.sup.e and R.sup.d in each case denote a hydrogen atom
and
[0060] X denotes a nitrogen atom,
[0061] the tautomers, their stereoisomers, the mixtures thereof and
the salts thereof.
[0062] Most particularly preferred compounds of general formula I
are those wherein
[0063] R.sup.a denotes a hydrogen atom,
[0064] R.sup.b denotes a 3-chloro-4-fluoro-phenyl group,
[0065] R.sup.c denotes a tetrahydrofuran-3-yloxy group,
[0066] R.sup.e and R.sup.d in each case denote a hydrogen atom
and
[0067] X denotes a nitrogen atom,
[0068] the tautomers, their stereoisomers, the mixtures thereof and
the salts thereof.
[0069] The following particularly preferred compound of general
formula I is mentioned by way of example: [0070]
4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-bu-
ten-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline
[0071] and the salts thereof.
[0072] The compounds of general formula I may be prepared by the
following methods, for example:
[0073] a) reacting a compound of general formula ##STR3##
wherein
[0074] R.sup.a, R.sup.b, R.sup.c and X are as hereinbefore defined
and R.sup.7 and R.sup.8, which may be identical or different,
denote C.sub.1-4-alkyl groups, with a compound of general formula
##STR4## wherein
[0075] R.sup.d and R.sup.e are as hereinbefore defined.
[0076] The reaction is expediently carried out in a solvent or
mixture of solvents such as tetrahydrofuran, tetrahydrofuran/water,
acetonitrile, acetonitrile/water, dioxane, ethyleneglycol dimethyl
ether, isopropanol, methylene chloride, dimethylformamide or
sulpholane, optionally in the presence of an inorganic or organic
base, e.g. sodium carbonate, potassium hydroxide or
1,8-diazabicyclo[5.4.0]undec-7-ene and optionally in the presence
of a lithium salt such as lithium chloride at temperatures between
-50 and 150.degree. C., but preferably at temperatures between -20
and 80.degree. C. The reaction may also be carried out with a
reactive derivative of the compound of general formula III, for
example the hydrate or a hemiacetal.
[0077] b) reacting a compound of general formula ##STR5##
wherein
[0078] R.sup.a, R.sup.b, R.sup.c and X are as hereinbefore defined
and Z.sup.1 denotes a leaving group such as a halogen atom or a
substituted sulphonyloxy group such as a chlorine or bromine atom,
a methanesulphonyloxy or p-toluenesulphonyloxy group, with a
compound of general formula ##STR6## wherein R.sup.d and R.sup.e
are as hereinbefore defined.
[0079] The reaction is expediently carried out in a solvent such as
isopropanol, butanol, tetrahydrofuran, dioxane, acetonitrile,
dimethylformamide, sulpholane, toluene or methylene chloride or
mixtures thereof, optionally in the presence of an inorganic or
organic base, e.g. sodium carbonate, potassium carbonate, potassium
hydroxide, triethylamine or N-ethyl-diisopropylamine and optionally
in the presence of a reaction accelerator such as an alkali metal
iodide at temperatures between -20 and 150.degree. C., but
preferably at temperatures between 0 and 100.degree. C. The
reaction may however also be carried out without a solvent or in an
excess of the compound of general formula V used.
[0080] In the reactions described hereinbefore, any reactive groups
present such as hydroxy, amino, alkylamino or imino groups may be
protected during the reaction by conventional protecting groups
which are cleaved again after the reaction.
[0081] For example, a protecting group for a hydroxy group may be a
trimethylsilyl, acetyl, trityl, benzyl or tetrahydropyranyl
group.
[0082] Protecting groups for an amino, alkylamino or imino group
may be a formyl, acetyl, trifluoroacetyl, ethoxycarbonyl,
tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or
2,4-dimethoxybenzyl group.
[0083] Any protecting group used is optionally subsequently cleaved
for example by hydrolysis in an aqueous solvent, e.g. in water,
isopropanol/water, acetic acid/water, tetrahydrofuran/water or
dioxane/water, in the presence of an acid such as trifluoroacetic
acid, hydrochloric acid or sulphuric acid or in the presence of an
alkali metal base such as sodium hydroxide or potassium hydroxide
or aprotically, e.g. in the presence of iodotrimethylsilane, at
temperatures between 0 and 120.degree. C., preferably at
temperatures between 10 and 100.degree. C.
[0084] However, a benzyl, methoxybenzyl or benzyloxycarbonyl group
is cleaved, for example, hydrogenolytically, e.g. with hydrogen in
the presence of a catalyst such as palladium/charcoal in a suitable
solvent such as methanol, ethanol, ethyl acetate or glacial acetic
acid, optionally with the addition of an acid such as hydrochloric
acid at temperatures between 0 and 100.degree. C., but preferably
at temperatures between 20 and 60.degree. C., and at a hydrogen
pressure of 1 to 7 bar, but preferably 3 to 5 bar. A
2,4-dimethoxybenzyl group, however, is preferably cleaved in
trifluoroacetic acid in the presence of anisol.
[0085] A tert.butyl or tert.butyloxycarbonyl group is preferably
cleaved by treating with an acid such as trifluoroacetic acid or
hydrochloric acid or by treating with iodotrimethylsilane,
optionally using a solvent such as methylene chloride, dioxane,
methanol or diethylether.
[0086] A trifluoroacetyl group is preferably cleaved by treating
with an acid such as hydrochloric acid, optionally in the presence
of a solvent such as acetic acid at temperatures between 50 and
120.degree. C. or by treating with sodium hydroxide solution
optionally in the presence of a solvent such as tetrahydrofuran at
temperatures between 0 and 50.degree. C.
[0087] Moreover, the compounds of general formula I obtained may be
resolved into their enantiomers and/or diastereomers, as mentioned
hereinbefore. Thus, for example, cis/trans mixtures may be resolved
into their cis and trans isomers, and compounds with at least one
optically active carbon atom may be separated into their
enantiomers.
[0088] Thus, for example, the cis/trans mixtures may be resolved by
chromatography into the cis and trans isomers thereof, the
compounds of general formula I obtained which occur as racemates
may be separated by methods known per se (cf. Allinger N. L. and
Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley
Interscience, 1971) into their optical antipodes and compounds of
general formula I with at least 2 asymmetric carbon atoms may be
resolved into their diastereomers on the basis of their
physical-chemical differences using methods known per se, e.g. by
chromatography and/or fractional crystallisation, and, if these
compounds are obtained in racemic form, they may subsequently be
resolved into the enantiomers as mentioned above.
[0089] The enantiomers are preferably separated by column
separation on chiral phases or by recrystallisation from an
optically active solvent or by reacting with an optically active
substance which forms salts or derivatives such as e.g. esters or
amides with the racemic compound, particularly acids and the
activated derivatives or alcohols thereof, and separating the
diastereomeric mixture of salts or derivatives thus obtained, e.g.
on the basis of their differences in solubility, whilst the free
antipodes may be released from the pure diastereomeric salts or
derivatives by the action of suitable agents. Optically active
acids in common use are e.g. the D- and L-forms of tartaric acid or
dibenzoyltartaric acid, di-O-p-tolyltartaric acid, malic acid,
mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid
or quinic acid. An optically active alcohol may be for example (+)
or (-)-menthol and an optically active acyl group in amides, for
example, may be a (+)-or (-)-menthyloxycarbonyl.
[0090] Furthermore, the compounds of formula I obtained may be
converted into the salts thereof, particularly for pharmaceutical
use into the physiologically acceptable salts with inorganic or
organic acids. Acids which may be used for this purpose include for
example hydrochloric acid, hydrobromic acid, sulphuric acid,
methanesulphonic acid, phosphoric acid, fumaric acid, succinic
acid, lactic acid, citric acid, tartaric acid or maleic acid.
[0091] As already mentioned hereinbefore, the compounds of general
formula I according to the invention and the physiologically
acceptable salts thereof have valuable pharmacological properties,
particularly an inhibiting effect on signal transduction mediated
by the Epidermal Growth Factor receptor (EGF-R), whilst this may be
achieved for example by inhibiting ligand bonding, receptor
dimerisation or tyrosinekinase itself. It is also possible to block
the transmission of signals to components located further
downstream.
[0092] The biological properties of the new compounds were
investigated as follows:
[0093] The inhibition of human EGF-receptor kinase was determined
using the cytoplasmatic tyrosine kinase domain (methionine 664 to
alanine 1186, based on the sequence published in Nature 309 (1984),
418). To do this, the protein was expressed in Sf9 insect cells as
a GST fusion protein using the Baculovirus expression system.
[0094] The enzyme activity was measured in the presence or absence
of the test compounds in serial dilutions. The polymer pEY (4:1)
produced by SIGMA was used as the substrate. Biotinylated pEY
(bio-pEY) was added as the tracer substrate. Every 100 .mu.l of
reaction solution contained 10 .mu.l of the inhibitor in 50% DMSO,
20 .mu.l of the substrate solution (200 mM HEPES pH 7.4, 50 mM
magnesium acetate, 2.5 mg/ml of poly(EY), 5 .mu.g/ml of bio-pEY)
and 20 .mu.l of enzyme preparation. The enzyme reaction was started
by the addition of 50 .mu.l of a 100 .mu.M ATP solution in 10 mM
magnesium chloride. The dilution of the enzyme preparation was
adjusted so that the incorporation of phosphate into the bio-pEY
was linear in terms of time and quantity of enzyme. The enzyme
preparation was diluted in 20 mM HEPES pH 7.4, 1 mM EDTA, 130 mM
common salt, 0.05% Triton X-100, 1 mM DTT and 10% glycerol.
[0095] The enzyme assays were carried out at ambient temperature
over a period of 30 minutes and were ended by the addition of 50
.mu.l of a stopping solution (250 mM EDTA in 20 mM HEPES pH 7.4).
100 .mu.l were placed on a streptavidin-coated microtitre plate and
incubated for 60 minutes at ambient temperature. Then the plate was
washed with 200 .mu.l of a washing solution (50 mM Tris, 0.05%
Tween 20). After the addition of 100 .mu.l of a HRPO-labelled
anti-PY antibody (PY20H Anti-PTyr:HRP produced by Transduction
Laboratories, 250 ng/ml) it was incubated for 60 minutes. Then the
microtitre plate was washed three times with 200 .mu.l of washing
solution. The samples were then combined with 100 .mu.l of a
TMB-peroxidase solution (A:B=1:1, Kirkegaard Perry Laboratories).
After 10 minutes the reaction was stopped. The extinction was
measured at OD.sub.450 nm with an ELISA reader. All data points
were measured three times.
[0096] The data were matched using an iterative calculation using
an analytical programme for sigmoidal curves (Graph Pad Prism
Version 3.0; sigmoid curves, variable pitch). All the iteration
data released showed a correlation coefficient of more than 0.9.
The maxima and minima of the curves showed a spread of at least a
factor of 5. The IC.sub.50 (concentration of active substance which
inhibits the activity of EGF-receptor kinase by 50%) was determined
from the curves.
[0097] The following results were obtained: TABLE-US-00001
Inhibition of EGF- Compound receptor kinase (Example No.) IC.sub.50
[nM] 1 1.5
[0098] The compounds of general formula I according to the
invention thus inhibit signal transduction by tyrosine kinases, as
demonstrated by the example of the human EGF receptor, and are
therefore useful for treating pathophysiological processes caused
by hyperfunction of tyrosine kinases. These are e.g. benign or
malignant tumours, particularly tumours of epithelial and
neuroepithelial origin, metastasisation and the abnormal
proliferation of vascular endothelial cells (neoangiogenesis).
[0099] The compounds according to the invention are also useful for
preventing and treating diseases of the airways and lungs which are
accompanied by increased or altered production of mucus caused by
stimulation by tyrosine kinases, e.g. in inflammatory diseases of
the airways such as chronic bronchitis, chronic obstructive
bronchitis, asthma, bronchiectasis, allergic or non-allergic
rhinitis or sinusitis, cystic fibrosis, .alpha.1-antitrypsin
deficiency, or coughs, pulmonary emphysema, pulmonary fibrosis and
hyperreactive airways.
[0100] The compounds are also suitable for treating diseases of the
gastrointestinal tract and bile duct and gall bladder which are
associated with disrupted activity of the tyrosine kinases, such as
may be found e.g. in chronic inflammatory changes such as
cholecystitis, Crohn's disease, ulcerative colitis, and ulcers in
the gastrointestinal tract or such as may occur in diseases of the
gastrointestinal tract which are associated with increased
secretions, such as Menetrier's disease, secreting adenomas and
protein loss syndrome.
[0101] In addition, the compounds of general formula I and the
physiologically acceptable salts thereof may be used to treat other
diseases caused by abnormal function of tyrosine kinases, such as
e.g. epidermal hyperproliferation (psoriasis), benign prostatic
hyperplasia (BPH), inflammatory processes, diseases of the immune
system, hyperproliferation of haematopoietic cells, treatment of
nasal polyps, etc.
[0102] By reason of their biological properties the compounds
according to the invention may be used on their own or in
conjunction with other pharmacologically active compounds, for
example in tumour therapy, in monotherapy or in conjunction with
other anti-tumour therapeutic agents, for example in combination
with topoisomerase inhibitors (e.g. etoposide), mitosis inhibitors
(e.g. vinblastine), compounds which interact with nucleic acids
(e.g. cis-platin, cyclophosphamide, adriamycin), hormone
antagonists (e.g. tamoxifen), inhibitors of metabolic processes
(e.g. 5-FU etc.), cytokines (e.g. interferons), antibodies, etc.
For treating respiratory tract diseases, these compounds may be
used on their own or in conjunction with other therapeutic agents
for the airways, such as substances with a secretolytic (e.g.
ambroxol, N-acetylcysteine), broncholytic (e.g. tiotropium or
ipratropium or fenoterol, salmeterol, salbutamol) and/or
anti-inflammatory activity (e.g. theophylline or glucocorticoids).
For treating diseases in the region of the gastrointestinal tract,
these compounds may also be administered on their own or in
conjunction with substances having an effect on motility or
secretion. These combinations may be administered either
simultaneously or sequentially.
[0103] These compounds may be administered either on their own or
in conjunction with other active substances by intravenous,
subcutaneous, intramuscular, intraperitoneal or intranasal route,
by inhalation or transdermally or orally, whilst aerosol
formulations are particularly suitable for inhalation.
[0104] For pharmaceutical use the compounds according to the
invention are generally used for warm-blooded vertebrates,
particularly humans, in doses of 0.01-100 mg/kg of body weight,
preferably 0.1-15 mg/kg. For administration they are formulated
with one or more conventional inert carriers and/or diluents, e.g.
with corn starch, lactose, glucose, microcrystalline cellulose,
magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric
acid, water, water/ethanol, water/glycerol, water/sorbitol,
water/polyethylene glycol, propylene glycol, stearyl alcohol,
carboxymethylcellulose or fatty substances such as hard fat or
suitable mixtures thereof in conventional galenic preparations such
as plain or coated tablets, capsules, powders, suspensions,
solutions, sprays or suppositories.
[0105] The following Examples are intended to illustrate the
present invention without restricting it:
Preparation of the Starting Compounds:
EXAMPLE I
4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(diethoxy-phosphoryl)-acetylamino]--
7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline
[0106] 60.07 g of diethoxyphosphorylacetic acid are placed in 750
ml of N,N-dimethylformamide and at ambient temperature combined
with 48.67 g of N,N'-carbonyldiimidazole. After the development of
gas has ceased 90.00 g of
4-[(3-chloro-4-fluoro-phenyl)amino]-6-amino-[(S)-(tetrahydrofuran-3-yl-
)oxy]-quinazoline are added and the reaction mixture is stirred for
about 4-5 hours at ambient temperature until the reaction is
complete. The reaction mixture is then heated gently in the water
bath and 750 ml of water are added twice. The thick suspension is
stirred overnight and the next morning another 350 ml of water are
added. The suspension is cooled in the ice bath, stirred for one
hour and suction filtered. The filter cake is washed again with 240
ml of N,N-dimethylformamide/water (1:2) and 240 ml of
diisopropylether and dried at 40.degree. C. in the circulating air
dryer.
[0107] Yield: 117.30 g of (88% of theory)
[0108] R.sub.f value: 0.37 (silica gel, methylene
chloride/methanol=9:1)
[0109] Mass spectrum (ESI.sup.+): m/z=553, 555 [M+H].sup.+
[0110] The following compounds are obtained analogously to Example
I:
(1)
4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(diethoxy-phosphoryl)-acetylami-
no]-7-[(R)-(tetrahydrofuran-3-yl)oxy]-quinazoline
[0111] Mass spectrum (ESI.sup.+): m/z=553, 555 [M+H].sup.+
(2)
4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(diethoxy-phosphoryl)-acetylami-
no]-7-cyclopropylmethoxy-quinazoline
[0112] melting point: 185-187.degree. C.
(3)
4-[(3-bromophenyl)amino]-6-[(diethoxy-phosphoryl)-acetylamino]-quinazo-
line
[0113] Mass spectrum (ESI.sup.-): m/z=491, 493 [M-H].sup.-
(4)
4-[(3-chloro-4-fluoro-phenyl)amino]-6-[(diethoxy-phosphoryl)-acetylami-
no]-7-cyclopentyloxy-quinazoline
[0114] R.sub.f value: 0.54 (silica gel, methylene
chloride/ethanol=20:1)
EXAMPLE II
Homomorpholin-4-yl-acetaldehyde-hydrochloride
[0115] Prepared by stirring (2.5 hours)
4-(2,2-dimethoxy-ethyl)-homomorpholine with semiconcentrated
hydrochloric acid at 80.degree. C. The solution obtained is further
reacted directly as in Example 1.
EXAMPLE III
4-(2,2-dimethoxy-ethyl)-homomorpholine
[0116] Prepared by stirring (5 hours) homomorpholine-hydrochloride
with bromoacetaldehyde-dimethylacetal in the presence of potassium
carbonate in N-methylpyrrolidinone at 80.degree. C.
[0117] R.sub.f value: 0.2 (silica gel, ethyl acetate/methanol/conc.
aqueous ammonia=90:10:1)
Preparation of the Final Compounds:
EXAMPLE 1
4-[(3-chloro-4-fluoro-phenyl)amino]-6-{[4-(homomorpholin-4-yl)-1-oxo-2-but-
en-1-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline
[0118] ##STR7##
[0119] A solution of 3.9 g of
4-[(3-chloro-4-fluoro-phenyl)amino]-6-[2-(diethoxy-phosphoryl)-acetylamin-
o]-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoline in 20 ml of
tetrahydrofuran is added to a solution of 300 mg of lithium
chloride in 20 ml of water at ambient temperature. Then 2.35 g of
potassium hydroxide flakes are added and the reaction mixture is
cooled to -3.degree. C. in an ice/acetone cooling bath. The
solution of the homomorpholin-4-yl-acetaldehyde hydrochloride
obtained in Example II is then added dropwise within 5 min at a
temperature of 0.degree. C. After the addition has ended the
reaction mixture is stirred for another 10 min at 0.degree. C. and
for a further hour at ambient temperature. For working up 100 ml of
ethyl acetate are added and the aqueous phase is separated off. The
organic phase is washed with saturated sodium chloride solution,
dried over magnesium sulphate and evaporated down. The crude
product is purified by chromatography over a silica gel column
using ethyl acetate/methanol/conc. methanolic ammonia as eluant.
The product obtained is stirred with a little diisopropyl ether,
suction filtered and dried.
[0120] Yield: 2.40 g of (63% of theory)
[0121] R.sub.f value: 0.09 (silica gel, ethyl
acetate/methanol/conc. aqueous ammonia=90:10:1)
[0122] Mass spectrum (ESI.sup.+): m/z=542, 544 [M+H].sup.+
[0123] The following compounds may also be prepared analogously to
the foregoing Examples and other methods known from the literature:
TABLE-US-00002 Example No. Structure (1) ##STR8## (2) ##STR9## (3)
##STR10## (4) ##STR11## (5) ##STR12## (6) ##STR13## (7) ##STR14##
(8) ##STR15## (9) ##STR16## (10) ##STR17## (11) ##STR18## (12)
##STR19## (13) ##STR20## (14) ##STR21## (15) ##STR22## (16)
##STR23## (17) ##STR24## (18) ##STR25## (19) ##STR26## (20)
##STR27## (21) ##STR28##
EXAMPLE 2
Coated Tablets Containing 75 mg of Active Substance
[0124] 1 tablet core contains: TABLE-US-00003 active substance 75.0
mg calcium phosphate 93.0 mg corn starch 35.5 mg
polyvinylpyrrolidone 10.0 mg hydroxypropylmethylcellulose 15.0 mg
magnesium stearate 1.5 mg 230.0 mg
Preparation:
[0125] The active substance is mixed with calcium phosphate, corn
starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half
the specified amount of magnesium stearate. Blanks 13 mm in
diameter are produced in a tablet-making machine and these are then
rubbed through a screen with a mesh size of 1.5 mm using a suitable
machine and mixed with the rest of the magnesium stearate. This
granulate is compressed in a tablet-making machine to form tablets
of the desired shape. [0126] Weight of core: 230 mg [0127] die: 9
mm, convex
[0128] The tablet cores thus produced are coated with a film
consisting essentially of hydroxypropylmethylcellulose. The
finished film-coated tablets are polished with beeswax. [0129]
Weight of coated tablet: 245 mg.
EXAMPLE 3
[0129] Tablets Containing 100 mg of Active Substance
Composition:
[0130] 1 tablet contains: TABLE-US-00004 active substance 100.0 mg
lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg
magnesium stearate 2.0 mg 220.0 mg
Method of Preparation:
[0131] The active substance, lactose and starch are mixed together
and uniformly moistened with an aqueous solution of the
polyvinylpyrrolidone. After the moist composition has been screened
(2.0 mm mesh size) and dried in a rack-type drier at 50.degree. C.
it is screened again (1.5 mm mesh size) and the lubricant is added.
The finished mixture is compressed to form tablets. [0132] Weight
of tablet: 220 mg [0133] Diameter: 10 mm, biplanar, facetted on
both sides and notched on one side.
EXAMPLE 4
[0133] Tablets Containing 150 mg of Active Substance
Composition:
[0134] 1 tablet contains: TABLE-US-00005 active substance 150.0 mg
powdered lactose 89.0 mg corn starch 40.0 mg colloidal silica 10.0
mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg 300.0
mg
Preparation:
[0135] The active substance mixed with lactose, corn starch and
silica is moistened with a 20% aqueous polyvinylpyrrolidone
solution and passed through a screen with a mesh size of 1.5 mm.
The granules, dried at 45.degree. C., are passed through the same
screen again and mixed with the specified amount of magnesium
stearate. Tablets are pressed from the mixture. [0136] Weight of
tablet: 300 mg [0137] die: 10 mm, flat
EXAMPLE 5
[0137] Hard Gelatine Capsules Containing 150 mg of Active
Substance
[0138] 1 capsule contains: TABLE-US-00006 active substance 150.0 mg
corn starch (dried) approx. 180.0 mg lactose (powdered) approx.
87.0 mg magnesium stearate 3.0 mg approx. 420.0 mg
Preparation:
[0139] The active substance is mixed with the excipients, passed
through a screen with a mesh size of 0.75 mm and homogeneously
mixed using a suitable apparatus. The finished mixture is packed
into size 1 hard gelatine capsules. [0140] Capsule filling: approx.
320 mg [0141] Capsule shell: size 1 hard gelatine capsule.
EXAMPLE 6
[0141] Suppositories Containing 150 mg of Active Substance
[0142] 1 suppository contains: TABLE-US-00007 active substance
150.0 mg polyethyleneglycol 1500 550.0 mg polyethyleneglycol 6000
460.0 mg polyoxyethylene sorbitan monostearate 840.0 mg 2,000.0
mg
Preparation:
[0143] After the suppository mass has been melted the active
substance is homogeneously distributed therein and the melt is
poured into chilled moulds.
EXAMPLE 7
Suspension Containing 50 mg of Active Substance
[0144] 100 ml of suspension contain: TABLE-US-00008 active
substance 1.00 g carboxymethylcellulose-Na-salt 0.10 g methyl
p-hydroxybenzoate 0.05 g propyl p-hydroxybenzoate 0.01 g glucose
10.00 g glycerol 5.00 g 70% sorbitol solution 20.00 g flavouring
0.30 g dist. water ad 100 ml
Preparation:
[0145] The distilled water is heated to 70.degree. C. The methyl
and propyl p-hydroxybenzoates together with the glycerol and sodium
salt of carboxymethylcellulose are dissolved therein with stirring.
The solution is cooled to ambient temperature and the active
substance is added and homogeneously dispersed therein with
stirring. After the sugar, the sorbitol solution and the flavouring
have been added and dissolved, the suspension is evacuated with
stirring to eliminate air. [0146] 5 ml of suspension contain 50 mg
of active substance.
EXAMPLE 8
[0146] Ampoules Containing 10 mg Active Substance
[0147] Composition: TABLE-US-00009 active substance 10.0 mg 0.01 N
hydrochloric acid q.s. double-distilled water ad 2.0 ml
Preparation:
[0148] The active substance is dissolved in the requisite amount of
0.01 N HCl, made isotonic with common salt, filtered sterile and
transferred into 2 ml ampoules.
EXAMPLE 9
Ampoules Containing 50 mg of Active Substance
[0149] Composition: TABLE-US-00010 active substance 50.0 mg 0.01 N
hydrochloric acid q.s. double-distilled water ad 10.0 ml
Preparation:
[0150] The active substance is dissolved in the necessary amount of
0.01 N HCl, made isotonic with common salt, filtered sterile and
transferred into 10 ml ampoules.
EXAMPLE 10
Capsules for Powder Inhalation Containing 5 mg of Active
Substance
[0151] 1 capsule contains: TABLE-US-00011 active substance 5.0 mg
lactose for inhalation 15.0 mg 20.0 mg
Preparation:
[0152] The active substance is mixed with lactose for inhalation.
The mixture is packed into capsules in a capsule-making machine
(weight of the empty capsule approx. 50 mg). TABLE-US-00012 weight
of capsule: 70.0 mg size of capsule 3
EXAMPLE 11
Solution for Inhalation for Hand-Held Nebulisers Containing 2.5 mg
Active Substance
[0153] 1 spray contains: TABLE-US-00013 active substance 2.500 mg
benzalkonium chloride 0.001 mg 1N hydrochloric acid q.s. ad 15.000
mg ethanol/water (50/50)
Preparation:
[0154] The active substance and benzalkonium chloride are dissolved
in ethanol/water (50/50). The pH of the solution is adjusted with 1
N hydrochloric acid. The resulting solution is filtered and
transferred into suitable containers for use in hand-held
nebulisers (cartridges).
[0155] Contents of the container: 4.5 g
* * * * *